Industry
Biotechnology
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Loading...
Open
61.24
Mkt cap
3.5B
Volume
739K
High
63.86
P/E Ratio
-52.23
52-wk high
71.71
Low
60.26
Div yield
N/A
52-wk low
7.79
Portfolio Pulse from
December 03, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:36 am
Portfolio Pulse from Benzinga Insights
September 06, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 06, 2024 | 3:27 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.